David Goode

The future of patient-derived xenografts in prostate cancer research.

Mitchell G Lawrence, Renea A Taylor, Georgia B Cuffe, Lisa S Ang, Ashlee K Clark, David L Goode, Laura H Porter, Clémentine Le Magnen, Nora M Navone, Jack A Schalken, Yuzhuo Wang, Wytske M van Weerden, Eva Corey, John T Isaacs, Peter S Nelson, Gail P Risbridger

Journal article  |  2023  |  Nat Rev Urol

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to st..

Abstract 4076: Single cell RNA analysis reveals heterogeneous sub populations in aggressive variants of prostate cancer

Rosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee K Clark, Laura H Porter, Mitchell G Lawrence, Renea A Taylor, Gail P Risbridger, Roxanne Toivanen, David L Goode

Journal article  |  2022  |  Cancer Research

Abstract Neuroendocrine prostate cancer (NEPC) represent an aggressive malignancy that results in poor patients out..

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

Anna Sofia Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon Keam, Heather Thorne, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin Blyth, Declan Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phil Darcy, Ygal Haupt, Scott G Williams, et al.

Journal article  |  2022  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

BACKGROUND: Aberrations in homologous recombination repair (HRR) genes are emerging as important biomarkers for personalized treat..

CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia

Athanasios Koulis, Natasha Di Costanzo, Catherine Mitchell, Stephen Lade, David Goode, Rita A Busuttil, Alex Boussioutas

Journal article  |  2022  |  BMC GASTROENTEROLOGY

BACKGROUND: Intestinal metaplasia (IM) is considered a key pivot point in the Correa model of gastric cancer (GC). It is histologi..

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma

Lorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt, Eric P Kusnadi, Jian Kang, Claire A Martin, Peter Lau, Riyaben Patel, Julie Lorent, David Papadopoli, Anna Trigos, Teresa Ward, Aparna D Rao, Emily J Lelliott, Karen E Sheppard, David Goode, Rodney J Hicks, Tony Tiganis, Kaylene J Simpson, Ola Larsson, et al.

Journal article  |  2022  |  NATURE COMMUNICATIONS

Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by residual disease that ultimately ..

CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition

Mitchell G Lawrence, Laura H Porter, Nicholas Choo, David Pook, Jeremy P Grummet, Carmel J Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L Goode, Elaine Sanij, Richard B Pearson, Ross D Hannan, Kaylene J Simpson, Renea A Taylor, Gail P Risbridger, Luc Furic

Journal article  |  2021  |  MOLECULAR CANCER THERAPEUTICS

Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologo..

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Gail P Risbridger, Ashlee K Clark, Laura H Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L Lister, David Pook, Carmel J Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B Madsen, Hong Wang, Michelle G Richards, Birunthi Niranjan, Samantha O'Dea, Linda Teng, William Wheelahan, et al.

Journal article  |  2021  |  NATURE COMMUNICATIONS

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-d..

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer

Laura H Porter, Andrew Bakshi, David Pook, Ashlee Clark, David Clouston, John Kourambas, David L Goode, Gail P Risbridger, Renea A Taylor, Mitchell G Lawrence

Journal article  |  2021  |  JOURNAL OF PATHOLOGY

Amplifications of the androgen receptor (AR) occur in up to 80% of men with castration-resistant prostate cancer (CRPC). Recent st..

Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment

Linda KH Teng, Brooke A Pereira, Shivakumar Keerthikumar, Cheng Huang, Birunthi Niranjan, Sophie N Lee, Michelle Richards, Ralf B Schittenhelm, Luc Furic, David L Goode, Mitchell G Lawrence, Renea A Taylor, Stuart J Ellem, Gail P Risbridger, Natalie L Lister

Journal article  |  2021  |  CANCERS

Mast cells (MCs) are important cellular components of the tumor microenvironment and are significantly associated with poor patien..

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Eric P Kusnadi, Anna S Trigos, Carleen Cullinane, David L Goode, Ola Larsson, Jennifer R Devlin, Keefe T Chan, David P De Souza, Malcolm J McConville, Grant A McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Katherine M Hannan, Jian Kang, Richard B Pearson

Journal article  |  2020  |  EMBO JOURNAL

Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our previous first-i..